Initiation of clinical studies with SL-701, a synthetic multi-peptide vaccine with enhanced immunostimulatory properties targeting multiple glioma-associated antigens, in adults with first recurrence of glioblastoma
Initiation of clinical studies with SL-701, a synthetic multi-peptide vaccine…
An Update on the Robust Clinical Activity of SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor on Cancer Stem Cells and Tumor Bulk, in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
An Update On The Robust Clinical Activity Of SL-401, a Targeted Therapy…
Preclinical Studies of SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Preclinical Studies of SL-401, a Targeted Therapy Directed To The Interleukin-3…
SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Possesses Preclinical Cytotoxic Activity Against Chronic Eosinophilic Leukemia
SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R),…
SL-401, a Novel Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Inhibits Plasmacytoid Dendritic Cell (pDC)-Induced Myeloma Cell Growth and Overcomes Drug Resistance
SL-401, A Novel Targeted Therapy Directed to the Interleukin-3 Receptor…
SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor on Cancer Stem Cells and Tumor Bulk, Has Broad Clinical Activity and Tolerability as a Single Agent in Patients With Advanced Hematological Malignancies
SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor on Cancer…
Clinical and Preclinical Activity of SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor on Cancer Stem Cells and Tumor Bulk of Hematologic Malignancies, Against Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Clinical and Preclinical Activity of SL-401, a Targeted Therapy Directed to the…
A Novel Agent SL-401 Targeting Interleukin-3 (IL-3)-Receptor Blocks Plasmacytoid Dendritic Cell (pDC)-Induced Myeloma Cell Growth and Overcomes Drug Resistance
A Novel Agent SL-401 Targeting Interleukin-3 (IL-3)-Receptor Blocks…
Peptide Vaccine Therapy for Childhood Gliomas: Interim Results of a Pilot Study
Peptide vaccine therapy for childhood gliomas: interim results of a pilot…
Anti-Leukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody-Conjugate in Acute Myeloid Leukemia
Anti-leukemia efficacy and mechanisms of action of SL-101, a novel anti-CD123…